SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-026112
Filing Date
2022-05-13
Accepted
2022-05-13 06:07:15
Documents
14
Period of Report
2022-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ea159763-8k_emmaus.htm   iXBRL 8-K 26177
2 ea159763ex99-1_emmaus.htm EX-99.1 42117
3 GRAPHIC image_001.jpg GRAPHIC 8577
  Complete submission text file 0001213900-22-026112.txt   255908

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20220513.xsd EX-101.SCH 2953
5 XBRL LABEL FILE emma-20220513_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20220513_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT ea159763-8k_emmaus_htm.xml XML 3291
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

IRS No.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 22920105
SIC: 2834 Pharmaceutical Preparations